Vikas Gupta, PharmD, BCPS, Becton, Dickinson and Company (Employee, Shareholder) Kalvin Yu, MD, BD (Employee) Jason M Pogue, PharmD, BCPS, BCIDP, Merck (Consultant)QPex (Consultant)Shionogi (Consultant)Utility Therapeutics (Consultant)VenatoRX (Consultant) Janet Weeks, PhD, Becton, Dickinson...
Zydus invests in Illexcor Therapeutics to advance novel oral therapy for sickle cell disease Mar 13, 2025 Karnataka Government allocates Rs 57 Cr to rebuild Bangalore Bioinnovation Centre after fire damage Mar 11, 2025 Sartorius to expand Bengaluru’s manufacturing capacity and ...
Bohlander1,3 1Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians-Universita¨t, Munich (LMU), Germany, 2Laboratory for Molecular Stem Cell Biology, Institute for Transplantation Diagnostics and Cell Therapeutics, Heinrich-Heine- Universita¨t, Du¨sseldorf, Germany,...
THERAPEUTICSContext: Breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1)-negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are distinguished by the dysregulat...
Vikas Gupta, PharmD, BCPS, Becton, Dickinson and Company (Employee, Shareholder) Kalvin Yu, MD, BD (Employee) Jason M Pogue, PharmD, BCPS, BCIDP, Merck (Consultant)QPex (Consultant)Shionogi (Consultant)Utility Therapeutics (Consultant)VenatoRX (Consultant) Janet Weeks, PhD, Becton, Dickinson...